Lam Research Co. (NASDAQ:LRCX) Shares Acquired by Trust Point Inc.

Trust Point Inc. boosted its stake in shares of Lam Research Co. (NASDAQ:LRCX) by 490.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,615 shares of the semiconductor company’s stock after purchasing an additional 3,834 shares during the quarter. Trust Point Inc.’s holdings in Lam Research were worth $333,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Atwood & Palmer Inc. purchased a new stake in Lam Research during the 4th quarter worth about $27,000. West Oak Capital LLC increased its holdings in Lam Research by 50.9% during the 4th quarter. West Oak Capital LLC now owns 400 shares of the semiconductor company’s stock worth $29,000 after purchasing an additional 135 shares during the period. Country Trust Bank increased its holdings in Lam Research by 900.0% during the 4th quarter. Country Trust Bank now owns 400 shares of the semiconductor company’s stock worth $29,000 after purchasing an additional 360 shares during the period. Finley Financial LLC purchased a new stake in Lam Research during the 4th quarter worth about $30,000. Finally, Householder Group Estate & Retirement Specialist LLC increased its holdings in Lam Research by 159.1% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 500 shares of the semiconductor company’s stock worth $36,000 after purchasing an additional 307 shares during the period. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Analysts Set New Price Targets

LRCX has been the topic of several recent research reports. Morgan Stanley upped their price target on Lam Research from $76.00 to $78.00 and gave the stock an “equal weight” rating in a report on Thursday, December 5th. B. Riley dropped their price objective on Lam Research from $132.50 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. BNP Paribas upgraded Lam Research to a “hold” rating in a report on Thursday, October 24th. The Goldman Sachs Group dropped their price objective on Lam Research from $96.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Finally, Barclays dropped their price objective on Lam Research from $90.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Seven analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $95.72.

Lam Research Stock Up 2.5 %

LRCX opened at $81.94 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.54 and a quick ratio of 1.73. The business has a 50 day simple moving average of $76.32 and a 200-day simple moving average of $78.33. The stock has a market capitalization of $105.18 billion, a P/E ratio of 24.89, a P/E/G ratio of 1.34 and a beta of 1.46. Lam Research Co. has a 12 month low of $68.87 and a 12 month high of $113.00.

Lam Research (NASDAQ:LRCX) last posted its quarterly earnings results on Wednesday, January 29th. The semiconductor company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.87 by $0.04. Lam Research had a return on equity of 51.86% and a net margin of 26.49%. On average, equities analysts anticipate that Lam Research Co. will post 3.69 earnings per share for the current fiscal year.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.